Leerink Partnrs Comments on UTHR FY2029 Earnings

United Therapeutics Corporation (NASDAQ:UTHR - Free Report) - Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of United Therapeutics in a report issued on Wednesday, July 23rd. Leerink Partnrs analyst R. Ruiz anticipates that the biotechnology company will post earnings per share of $31.83 for the year. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The company's quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.17 earnings per share.

UTHR has been the topic of several other reports. Wells Fargo & Company reissued an "equal weight" rating and issued a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Cantor Fitzgerald began coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 target price on the stock. Morgan Stanley reduced their price target on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. Wall Street Zen cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Finally, UBS Group reduced their price target on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research report on Monday, June 30th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $383.08.

United Therapeutics Trading Down 0.6%

Shares of NASDAQ UTHR traded down $1.91 during midday trading on Thursday, reaching $304.50. 310,921 shares of the stock were exchanged, compared to its average volume of 372,488. The company has a market capitalization of $13.74 billion, a P/E ratio of 12.15, a P/E/G ratio of 6.64 and a beta of 0.53. United Therapeutics has a 52-week low of $266.98 and a 52-week high of $417.82. The stock has a 50 day moving average price of $300.01 and a 200-day moving average price of $315.85.

Institutional Trading of United Therapeutics

Several institutional investors have recently added to or reduced their stakes in UTHR. Chung Wu Investment Group LLC bought a new stake in United Therapeutics during the second quarter valued at $29,000. SVB Wealth LLC bought a new stake in United Therapeutics during the first quarter valued at $32,000. Dunhill Financial LLC increased its stake in United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 50 shares during the last quarter. Geneos Wealth Management Inc. increased its stake in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Finally, Sound Income Strategies LLC bought a new stake in United Therapeutics during the first quarter valued at $49,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity at United Therapeutics

In related news, Director Richard Giltner sold 3,036 shares of the company's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the sale, the director directly owned 19,384 shares of the company's stock, valued at $5,613,606.40. This represents a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Nilda Mesa sold 645 shares of the company's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total transaction of $187,043.55. Following the completion of the sale, the director directly owned 4,883 shares in the company, valued at $1,416,021.17. This represents a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 81,681 shares of company stock valued at $24,628,589. Insiders own 10.30% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.